Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

Gut microbiota / Evidence-based microbiome knowledge (incl. AI chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

Biﬁdobacterium breve & Adiposity / Obesity

Welcome to meRfi-GM!

Please register to continue your trial period!

meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

Clinical data

XXX - Biﬁdobacterium breve B-3 & Adiposity / Obesity

In this randomized, double-blind, parallel-group comparative clinical trial, it was discovered that Biﬁdobacterium breve B-3 leads to a significant reduction in fat mass by the 12th week when compared to the placebo group. Furthermore, significant correlations were found between changes in specific blood parameters and the alterations in fat mass within the B-3 group (1).

References

(1) Minami et al. 2015 J Nutr Sci. 4: e17

see also:
Adiposity / Obesity & Drugs / Treatments
[Probiotics (living agents) & Adiposity / O…

References (Sources)

Effects of Biﬁdobacterium breve B3 on body fat reductions in pre-obese adults: a randomized, double-blind, placebo-controlled trial.
Minami et al. 2018 Biosci Microbiota Food Health. 37: 67–75
Oral administration of Biﬁdobacterium breve B-3 modiﬁes metabolic functions in adults with obese tendencies in a randomised controlled trial
Minami et al. 2015 J Nutr Sci. 4: e17

AI Chat

5/29/2026

Chat with our artificial intelligence:

Start chat!